Study of TRI-611 for ALK-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new investigational drug called TRI-611 for people with ALK-positive non-small cell lung cancer. It is designed for people who have already tried other ALK-targeted medicines, especially lorlatinib, and whose cancer may have stopped responding to them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must be ALK-positive (a specific gene change).
- The cancer must be measurable on scans (like CT or MRI).
- Your bone marrow and major organs (kidneys, liver) must be working well enough.
- Depending on the part of the study, you must have already taken between 2 and 3 ALK-targeted pills (TKIs) – or more than 3 – and one of them must have been lorlatinib (Lorbrena) or neladalkib.
- You cannot have a different gene change that is known to make ALK medicines stop working.
- You must not have had major surgery in the last 4 weeks or be getting other cancer treatments now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This trial looks at why ALK-positive lung cancer stops responding to the targeted drug lorlatinib, and what treatments might work next. It's for people whose cancer has progressed during first-line lorlatinib therapy.
This trial tests a combination of two drugs for people with a specific type of advanced lung cancer that has a change in the ALK gene. The goal is to see if this combination works better than current treatments and to use a blood test to guide therapy.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study tests if the targeted drug lorlatinib works better than the usual combination of chemotherapy and radiation for people with a specific type of advanced lung cancer that has a change in the ALK gene. It aims to shrink tumors and stop them from growing.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
Hear when a new ALK-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.